Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PENTHRANE vs ABILIFY MAINTENA KIT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Penthrane (methoxyflurane) is a volatile halogenated ether anesthetic that potentiates GABA-A receptor activity and inhibits NMDA receptors, leading to neuronal hyperpolarization and central nervous system depression. It also sensitizes the myocardium to catecholamines and produces nephrotoxic fluoride ions via metabolism.
Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors, stabilizing dopamine and serotonin activity.
Induction and maintenance of general anesthesia,Analgesia for short-duration procedures (off-label)
Treatment of schizophrenia,Maintenance monotherapy for bipolar I disorder,Adjunctive treatment of major depressive disorder (off-label),Irritability associated with autistic disorder (off-label),Tourette's disorder (off-label)
0.2-0.5% inspired concentration via inhalation for analgesia; for general anesthesia, up to 2% inspired via vaporizer.
400 mg IM once monthly after establishing tolerability with oral aripiprazole.
Terminal elimination half-life ranges from 1.5 to 4 hours, reflecting slow washout due to high fat solubility and prolonged release from adipose tissue. Clinically, this can lead to prolonged sedation and risk of fluoride-induced nephrotoxicity.
Aripiprazole: 75-146 hours; dehydro-aripiprazole: 94-146 hours. Long half-life allows monthly intramuscular dosing.
Primarily hepatic via cytochrome P450 enzymes (CYP2E1), releasing inorganic fluoride ions; approximately 50% is metabolized.
Primarily hepatic via CYP2D6 and CYP3A4; active metabolite dehydro-aripiprazole.
Approximately 50% of absorbed methoxyflurane is eliminated unchanged by the lungs; the remainder is metabolized, primarily via hepatic CYP450 isoenzymes, with fluoride ion and other metabolites excreted renally. Biliary/fecal elimination is negligible (<1%).
Renal (approximately 25% unchanged and 55% as metabolites); fecal (approximately 20% as metabolites).
40–50% bound to plasma proteins, primarily albumin.
Aripiprazole is >99% bound to serum albumin and alpha-1-acid glycoprotein.
Vd approx 2.0–3.5 L/kg, reflecting extensive distribution into adipose tissue and slow equilibration.
Aripiprazole: 4.9 L/kg (range 3.7-7.2 L/kg), indicating extensive tissue distribution.
Inhalation: 100% via pulmonary route (no first-pass metabolism). Not administered orally or parenterally in clinical use.
IM (Abilify Maintena): 100% relative to oral aripiprazole after 5 monthly doses; oral: 87%.
No specific GFR-based dose adjustments; use with caution in severe renal impairment due to potential nephrotoxicity from fluoride ions.
No adjustment for mild/moderate impairment; caution in severe impairment (Cr Cl <30 m L/min).
No specific Child-Pugh based modifications; use with caution in severe hepatic impairment due to potential hepatotoxicity.
No adjustment for mild impairment; moderate to severe (Child-Pugh class B or C): reduce dose to 300 mg/month.
Not recommended for children due to risk of nephrotoxicity and hepatotoxicity; alternative agents preferred.
Not approved for pediatric use.
Use lower inspired concentrations (e.g., 0.2-0.5%) and monitor closely for hypotension and respiratory depression; consider reduced dose due to decreased renal and hepatic function.
Use cautiously due to increased sensitivity; consider lower doses and monitor for adverse effects.
Not approved for use in the United States; has been associated with fatal hepatotoxicity and nephrotoxicity, particularly when used at high doses or for prolonged periods.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
Hepatotoxicity and nephrotoxicity due to fluoride ion accumulation; myocardial sensitization to catecholamines; malignant hyperthermia risk; respiratory depression; dose-dependent renal impairment.
Increased mortality in elderly dementia patients; suicidal thoughts and behaviors; neuroleptic malignant syndrome; tardive dyskinesia; metabolic changes (hyperglycemia, dyslipidemia, weight gain); orthostatic hypotension; leukopenia/neutropenia; seizure risk; dysphagia; body temperature dysregulation; pathological gambling and other impulse control disorders.
Hypersensitivity to halogenated anesthetics; known or suspected susceptibility to malignant hyperthermia; significant hepatic or renal impairment; concurrent use of nephrotoxic agents.
Hypersensitivity to aripiprazole or any excipients in the formulation.
No direct food interactions are documented. However, methoxyflurane metabolism may be affected by hepatic enzyme inducers or inhibitors. Avoid excessive consumption of grapefruit juice as it may inhibit CYP2E1, potentially altering drug metabolism. Maintain adequate hydration to help reduce the risk of nephrotoxicity.
No specific food interactions. Grapefruit/grapefruit juice may increase aripiprazole levels (CYP3A4 inhibition). Avoid excessive alcohol consumption.
First trimester: Limited human data; animal studies show fetal toxicity at high doses. Potential risk of congenital anomalies cannot be excluded. Second and third trimesters: May cause fetal hypotension and bradycardia; avoid prolonged or high-dose exposure. Near term: Risk of neonatal respiratory depression.
First trimester: Limited data, but aripiprazole is not a major human teratogen based on available studies. Second and third trimesters: Neonates exposed to antipsychotics, including aripiprazole, during the third trimester are at risk for extrapyramidal and/or withdrawal symptoms post-delivery.
Unknown if excreted in human milk. M/P ratio not established. Caution advised; consider benefits of breastfeeding vs. potential risk to infant.
Aripiprazole is excreted in human breast milk; the estimated infant dose is 0.7–1.4% of maternal weight-adjusted dose. M/P ratio: approximately 0.3–0.5. Limited data suggest no adverse effects in breastfed infants, but long-term safety is unknown.
No specific dose adjustments recommended due to limited data. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may reduce efficacy; use lowest effective dose for shortest duration.
No specific dose adjustment recommended based on pharmacokinetic changes; however, therapeutic drug monitoring may be considered due to altered metabolism in pregnancy. The long-acting injectable formulation (Abilify Maintena) requires careful timing of doses postpartum to avoid relapse.
Penthrane (methoxyflurane) is a volatile inhalational anesthetic with potent analgesic properties at subanesthetic doses. It is primarily used for emergency pain relief via a handheld inhaler (Penthrox). Key clinical pearls: (1) Nephrotoxicity is dose-dependent due to inorganic fluoride metabolites; limit exposure to a maximum of 6 m L over a week. (2) Avoid concurrent use of tetracyclines or aminoglycosides due to increased nephrotoxic risk. (3) Caution in patients with renal impairment, hepatic disease, or malignant hyperthermia susceptibility. (4) Rapid onset of analgesia within 2-5 breaths; monitor for excessive sedation or respiratory depression. (5) Do not use in patients with cardiovascular instability or hypovolemia as it can cause myocardial depression.
Administer every 4 weeks by intramuscular injection only. Do not substitute for oral aripiprazole on a mg-per-mg basis due to different pharmacokinetics. Requires initiation and continuation with oral aripiprazole for 14 days to establish tolerability. Monitor for neuroleptic malignant syndrome, tardive dyskinesia, and metabolic changes. Dose adjustments needed in patients with known CYP2D6 poor metabolizer status or concurrent use of strong CYP2D6 or CYP3A4 inhibitors.
Penthrane is used to relieve moderate to severe pain from trauma or procedures.,Inhale from the device as instructed; do not swallow the liquid.,You may feel drowsy or dizzy; avoid driving or operating machinery for at least 24 hours after use.,Do not consume alcohol or take other central nervous system depressants without consulting your doctor.,Report any signs of kidney injury such as decreased urination, swelling, or fatigue.,Use only as directed and do not exceed the prescribed dose or duration.,Keep the inhaler out of reach of children and do not share with others.
This medication is given as an injection every 4 weeks by a healthcare professional.,Do not stop taking your oral aripiprazole until your doctor tells you to.,Seek emergency care if you experience fever, muscle stiffness, confusion, or irregular heartbeat.,Avoid alcohol and driving until you know how this medicine affects you.,Report any uncontrolled movements of the face, tongue, or other body parts to your doctor.,Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PENTHRANE vs ABILIFY MAINTENA KIT, answered by our medical review team.
PENTHRANE is a Inhaled Anesthetic that works by Penthrane (methoxyflurane) is a volatile halogenated ether anesthetic that potentiates GABA-A receptor activity and inhibits NMDA receptors, leading to neuronal hyperpolarization and central nervous system depression. It also sensitizes the myocardium to catecholamines and produces nephrotoxic fluoride ions via metabolism.. ABILIFY MAINTENA KIT is a Atypical antipsychotic that works by Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors, stabilizing dopamine and serotonin activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PENTHRANE and ABILIFY MAINTENA KIT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PENTHRANE is: 0.2-0.5% inspired concentration via inhalation for analgesia; for general anesthesia, up to 2% inspired via vaporizer.. The standard adult dose of ABILIFY MAINTENA KIT is: 400 mg IM once monthly after establishing tolerability with oral aripiprazole.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PENTHRANE and ABILIFY MAINTENA KIT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PENTHRANE is classified as Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Potential risk of congenital anomalies cannot be excluded. Second and third trimesters: May c. ABILIFY MAINTENA KIT is classified as Category C. First trimester: Limited data, but aripiprazole is not a major human teratogen based on available studies. Second and third trimesters: Neonates exposed to antipsychotics, includin. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.